Colorectal Cancer - Germany Drug Forecasts and Treatment Analysis to 2020


#29458

152pages

GlobalData

$ 3000

In Stock


GlobalData, the industry analysis specialist, has released its new report, “Colorectal Cancer Germany Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the German colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the German colorectal cancer therapeutics market. It analyses the treatment usage patterns in the German colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the German colorectal cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

The scope of the report includes:

  • An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized German colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020.
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product.
  • Technology trends analytic framework to assess strength of pipeline.
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
  • An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the German Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
  • Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in Germany.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by
  • Understanding the trends shaping and driving the German colorectal cancer therapeutics market.
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the German colorectal cancer therapeutics market till 2020.
  • Quantifying patient population in Germany to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters.
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
  • Develop and design your in-licensing and out-licensing strategies by
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Track drug sales in the German colorectal cancer therapeutics market from 2001 to 2020
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • What's the next big thing in the German Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize. 
Table Of Content

1 Table of contents 3
1.1 List of Tables 6
1.2 List of Figures 7

2 Disease Overview 9
2.1 Overview 9
2.2 Epidemiology 10
2.3 Etiology 10
2.4 Symptoms 11
2.4.1 Colon Cancer 11
2.4.2 Cancer 11
2.5 Diagnosis 12
2.5.1 FOBT 12
2.5.2 Endoscopy 12
2.5.3 Optical Colonoscopy 13
2.5.4 Virtual Colonoscopy 13
2.5.5 Double Contrast Barium Enema (DCBE) 13
2.6 Pathology 13
2.6.1 Grading 14
2.7 Treatment 14
2.7.1 Colon Cancer Treatment by Stage 15
2.7.2 Rectal Cancer Treatment by Stage 17
2.7.3 Chemotherapy Options 19
2.8 Treatment Guidelines 22

3 Market Characterization 23
3.1 Germany 23
3.1.1 Market Size 23
3.1.2 Drivers and Barriers 28
3.1.3 Impact on the Market 29
3.1.4 Forecasts 30
3.1.5 Drug Sales 36
3.1.6 Pricing and Reimbursements 38
3.2 Key Takeaway 39

4 Competitor Assessment 40
4.1 Strategic Competitor Assessment 40
4.1.1 Overview 40
4.1.2 Benchmarking 40
4.1.3 Current Competitor Assessment 43
4.2 Launch Analysis and Sales Forecasts 44
4.2.1 Market Share Analysis of Drugs 44
4.3 Product Profiles 45
4.3.1 Avastin (bevacizumab) 46
4.3.2 Erbitux (cetuximab) 49
4.3.3 Xeloda (capecitabine) 54
4.3.4 Vectibix (panitumumab) 58
4.3.5 Eloxatin (oxaliplatin) 63
4.3.6 Camptosar (irinotecan) 68
4.3.7 Fluorouracil (5-FU) 70
4.3.8 Leucovorin (folinic acid) 71
4.4 Key Takeaway 72

5 Pipeline Assessment 73
5.1 Overview 73
5.2 Pipeline Analysis by Phase of Development 74
5.3 Pipeline by Mechanism of Action 75
5.4 Strategic Pipeline Assessment 76
5.4.1 Technology Trends Analytical Framework 76
5.5 Trends in Colorectal Cancer Pipeline 77
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer 77
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline 77
5.5.3 Failure of key Molecules in Phase II and Phase III Development 77
5.6 Partners in Development 78
5.6.1 Licensing Agreements by Phase of Development 78
5.6.2 Licensing Agreements by Geography 80
5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology 81
5.7 Most Promising Drugs Profiles 82
5.7.1 Aflibercept 82
5.7.2 Brivanib 84
5.7.3 OncoVAX 86
5.7.4 TroVax 88
5.7.5 KRX-0401 (Perifosine) 90
5.8 Colorectal Cancer Pipeline Preclinical Phase 91
5.9 Colorectal Cancer Pipeline Phase I 92
5.10 Colorectal Cancer Pipeline Phase II 93
5.11 Colorectal Cancer Pipeline Phase III 99
5.12 Key Takeaway 102

6 Unmet Need and Target Product Profile 103
6.1 Unmet Need 104
6.2 Opportunity for Target Product 105
6.3 Target Product Profile 106
6.3.1 Ideal Characteristics 106
6.3.2 Target Product Description 106
6.4 Key Takeaway 107

7 Strategic Assessment 108
7.1 Key Events Impacting the Future Market 108
7.2 Market Impact Analysis 108
7.3 Future Market Scenario 109
7.4 Company Analysis 110
7.4.1 Market Leadership 110
7.4.2 Future Players in the Market 110
7.5 Key Takeaway 110

8 Company Profiles 111
8.1 F. Hoffmann La Roche 111
8.1.1 Business Description 111
8.1.2 Financial Overview 111
8.1.3 SWOT Analysis 111
8.2 Bristol-Myers Squibb 113
8.2.1 Business Description 113
8.2.2 Financial Overview 113
8.2.3 SWOT Analysis 114
8.3 Sanofi-Aventis 115
8.3.1 Business Description 115
8.3.2 Financial Overview 115
8.3.3 SWOT Analysis 115
8.4 Debiopharm Group 116
8.4.1 Business Description 116
8.5 Merck KGaA 116
8.5.1 Business Description 116
8.5.2 Financial Overview 117
8.5.3 SWOT Analysis 117
8.6 Regeneron 118
8.6.1 Business Description 118
8.6.2 Financial Overview 119
8.6.3 SWOT Analysis 119
8.7 Vaccinogen BD 120
8.7.1 Overview 120
8.7.2 SWOT Analysis 121
8.8 Oxford BioMedica 121
8.8.1 Business Description 121
8.8.2 Financial Overview 122
8.8.3 SWOT Analysis 123
8.9 Auron Healthcare GmbH 124
8.9.1 Company Overview 124
8.10 AEterna Zentaris 124
8.10.1 Business Description 124
8.10.2 Financial Overview 124
8.10.3 SWOT Analysis 125
8.11 Keryx 127
8.11.1 Business Description 127
8.11.2 Financial Overview 128
8.11.3 SWOT Anlaysis 128
8.12 Abbott Laboratories 131
8.12.1 Business Description 131
8.12.2 Financial Performance 131
8.12.3 SWOT Analysis 131
8.13 Pfizer 133
8.13.1 Business Description 133
8.13.2 Financial Overview 134
8.13.3 SWOT Analysis 134
8.14 Light Sciences Oncology, Inc 135
8.14.1 Business Description 135
8.14.2 Financial Overview 135
8.14.3 SWOT Analysis 135

9 Deals Analysis 138
9.1 Key Highlights 138
9.2 Key Deals Analysis 139
9.2.1 Eli Lilly Acquires ImClone 139
9.2.2 Astellas Pharma Acquires OSI Pharmaceuticals 139
9.2.3 Takeda Acquires IDM Pharma 139
9.2.4 Alchemia Acquires Meditech 139
9.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron 139
9.2.6 BBM Holdings to Acquire YM Biosciences 139
9.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis 139
9.2.8 Peptech Acquires cancer Antibodies from Scancell 140
9.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs 140
9.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc 140
9.3 Deals Analysis by Geography 141
9.4 Deals Analysis by Deal Size 142

10 Expert Opinion 143
10.1 Germany 143

11 Appendix 144
11.1 Market Definitions 144
11.2 Abbreviations 144
11.3 Research Methodology 146
11.3.1 Coverage 146
11.3.2 Secondary Research 146
11.3.3 Forecasting 147
11.3.4 Primary Research 150
11.3.5 Expert Panel validation 150
11.3.6 Contact Us 150
11.3.7 Disclaimer 150
11.3.8 Sources 151

Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010 10
Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010 14
Table 3: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 20012009 23
Table 4: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20012009 24
Table 5: Colorectal Cancer Therapeutics Market, Germany, Patient Volume (000), 20012009 25
Table 6: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20012009 26
Table 7: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 20092020 30
Table 8: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20092020 31
Table 9: Colorectal Cancer Therapeutics Market, Germany, Patient Volume (000), 20092020 32
Table 10: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20092020 33
Table 11: Colorectal Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2010 37
Table 12: Colorectal Cancer Therapeutics Market, Germany, Drug Sales ($m), 2011-2020 38
Table 13: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010 42
Table 14: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010 45
Table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010 46
Table 16: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010 50
Table 17: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010 55
Table 18: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010 59
Table 19: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010 60
Table 20: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 64
Table 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010 65
Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010 81
Table 23: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010 91
Table 24: Colorectal Cancer, Global, Phase I Pipeline, July 2010 92
Table 25: Colorectal Cancer, Global, Phase II Pipeline, July 2010 93
Table 26: Colorectal Cancer, Global, Phase III Pipeline, July 2010 99
Table 27: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010 104
Table 28: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010 106
Table 29: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010 106
Figure 1: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010 22
Figure 2: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010 22
Figure 3: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 20012009 23
Figure 4: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20012009 24
Figure 5: Colorectal Cancer Therapeutics Market, Germany, Patient Volume, 20012009 25
Figure 6: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20012009 26
Figure 7: Colorectal Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009 28
Figure 8: Colorectal Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2010 29
Figure 9: Colorectal Cancer Therapeutics Market, Germany, Sales Value ($bn), 20092020 30
Figure 10: Colorectal Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20092020 31
Figure 11: Colorectal Cancer Therapeutics Market, Germany, Patient Volume, 20092020 32
Figure 12: Colorectal Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20092020 33
Figure 13: Colorectal Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 20092020 35
Figure 14: Colorectal Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2020 36
Figure 15: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010 41
Figure 16: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010 43
Figure 17: Colorectal Cancer Therapeutics Market, Germany, Sales Forecast Split by Therapies, 2001-2020 44
Figure 18: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 20042010 48
Figure 19: Colorectal Cancer Therapeutics Market, Germany, Avastin, Sales Forecast ($m), 2005-2020 49
Figure 20: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 20042010 52
Figure 21: Colorectal Cancer Therapeutics Market, Germany, Erbitux, Sales Forecast ($m), 2004-2020 53
Figure 22: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010 54
Figure 23: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010 57
Figure 24: Colorectal Cancer Therapeutics Market, Germany, Xeloda, Sales Forecast ($m), 2001-2020 58
Figure 25: Colorectal Cancer Therapeutics Market, Global, Vectibix, Life Cyle Management Activities, 2010 62
Figure 26: Colorectal Cancer Therapeutics Market, Germany, Vectibix, Sales Forecast ($m), 2008-2020 63
Figure 27: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010 64
Figure 28: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Life Cyle Management Activities, 2010 66
Figure 29: Colorectal Cancer Therapeutics Market, Germany, Eloxatin, Sales Forecast ($m), 2001-2020 67
Figure 30: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure 68
Figure 31: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cyle Management Activities, 2010 69
Figure 32: Colorectal Cancer Therapeutics Market, Germany, Camptosar, Sales Forecast ($m), 2001-2020 70
Figure 33: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure 70
Figure 34: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure 71
Figure 35: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010 73
Figure 36: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010 74
Figure 37: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010 75
Figure 38: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 76
Figure 39: Colorectal Cancer Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2010 77
Figure 40: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010 78
Figure 41: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010 80
Figure 42: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010 81
Figure 43: Colorectal Cancer Therapeutics Market, Germany, Aflibercept Sales Forecast ($m), 2011-2020 84
Figure 44: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010 84
Figure 45: Colorectal Cancer Therapeutics Market, Germany, Brivanib Sales Forecasts ($m), 2013-2020 86
Figure 46: Colorectal Cancer Therapeutics Market, Germany, OncoVAX Sales Forecast ($m), 2011-2020 88
Figure 47: Colorectal Cancer Therapeutics Market, Germany, TroVax Sales Forecast ($m), 2014-2020 89
Figure 48: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010 90
Figure 49: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010 103
Figure 50: Colorectal Cancer Therapeutics Market, Germany, Opportunity and Unmet Need, 2010 105
Figure 51: Colorectal Cancer, Global, Key Events Impacting the Future Market 108
Figure 52: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010 109
Figure 53: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010 138
Figure 54: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography (%), 2010 141
Figure 55: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010 142
Figure 56: Colorectal Cancer Therapeutics Market, Germany, Key Data Inputs from Key Opinion Leader Interviews, July 2010 143
Figure 57: GlobalData Market Forecasting Model 149